Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 5/2022

09.07.2021 | Original Article

Effect of Paclitaxel-Coated Balloon Angioplasty on Side Branch Lesion and Cardiovascular Outcomes in Patients with De Novo True Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention

verfasst von: Youmei Li, Qi Mao, Huanyun Liu, Denglu Zhou, Jianhua Zhao

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the effects of paclitaxal-coated balloon (PCB) versus conventional balloon (CB) on side branch (SB) lesion and cardiovascular outcomes in patients with de novo true bifurcation lesions.

Methods

In total, 219 patients with de novo true bifurcation lesions were enrolled and divided into PCB group (102 cases) and CB group (117 cases) according to angioplasty strategy in SB. Drug-eluting stent (DES) was implanted in main vessel (MV) for each subject. All subjects underwent a 12-month follow-up for late lumen loss (LLL), restenosis, and major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI). MACEs included cardiac death, nonfatal myocardial infarction, and unstable angina requiring admission.

Results

There were no differences in diameter, minimum lumen diameter (MLD), and stenosis for bifurcation lesions between the two groups before and immediately after PCI (P > 0.05). After 12-month follow-up, no differences occurred in MV-MLD and MV-LLL between the two groups (P > 0.05); SB-MLD in PCB group was higher than that in CB group (1.97 ± 0.36 mm vs. 1.80 ± 0.43 mm, P = 0.007); SB-LLL in PCB group was lower than that in CB group (0.11 ± 0.18 mm vs. 0.19 ± 0.25 mm, P = 0.024). Multivariate COX analyses indicated that PCB group had lower MACE risk than CB group (HR = 0.480, 95%CI 0.244–0.941, P = 0.033).

Conclusion

PCB could decrease SB-LLL and MACE risk in patients with de novo true coronary bifurcation lesion 12 months after single-DES intervention.
Literatur
1.
Zurück zum Zitat Lassen JF, Holm NR, Banning A, et al. Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. EuroIntervention. 2016;12:38–46.CrossRef Lassen JF, Holm NR, Banning A, et al. Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. EuroIntervention. 2016;12:38–46.CrossRef
2.
Zurück zum Zitat Généreux P, Kumsars I, Lesiak M, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. J Am Coll Cardiol. 2015;65:533–43.CrossRef Généreux P, Kumsars I, Lesiak M, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. J Am Coll Cardiol. 2015;65:533–43.CrossRef
3.
Zurück zum Zitat Al Suwaidi J, Berger PB, Rihal CS, et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol. 2000;35:929–36.CrossRef Al Suwaidi J, Berger PB, Rihal CS, et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol. 2000;35:929–36.CrossRef
4.
Zurück zum Zitat Kumsars I, Holm NR, Niemelä M, et al. Randomised comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch: the Nordic-Baltic Bifurcation Study IV. Open Heart. 2020;7:e947.CrossRef Kumsars I, Holm NR, Niemelä M, et al. Randomised comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch: the Nordic-Baltic Bifurcation Study IV. Open Heart. 2020;7:e947.CrossRef
5.
Zurück zum Zitat Zamani P, Kinlay S. Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis. Catheter Cardiovasc Interv. 2011;77:202–12.CrossRef Zamani P, Kinlay S. Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis. Catheter Cardiovasc Interv. 2011;77:202–12.CrossRef
6.
Zurück zum Zitat Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease. J Am Coll Cardiol. 2020;75:1061–73.CrossRef Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease. J Am Coll Cardiol. 2020;75:1061–73.CrossRef
7.
Zurück zum Zitat Rissanen TT, Uskela S, Eränen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet. 2019;394:230–9.CrossRef Rissanen TT, Uskela S, Eränen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet. 2019;394:230–9.CrossRef
8.
Zurück zum Zitat Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11:13–23.CrossRef Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11:13–23.CrossRef
9.
Zurück zum Zitat Ang H, Lin J, Huang YY, et al. Drug-coated balloons: technologies and clinical applications. Curr Pharm Des. 2018;24:381–96.CrossRef Ang H, Lin J, Huang YY, et al. Drug-coated balloons: technologies and clinical applications. Curr Pharm Des. 2018;24:381–96.CrossRef
10.
Zurück zum Zitat Vos Nicola S, Fagel Nick D, Amoroso Giovanni, Herrman Jean-Paul R, Patterson Mark S, Piers Lieuwe H, van der Schaaf René J, Slagboom Ton, Vink Maarten A. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction. JACC Cardiovasc Interv. 2019;12:1691–9.CrossRef Vos Nicola S, Fagel Nick D, Amoroso Giovanni, Herrman Jean-Paul R, Patterson Mark S, Piers Lieuwe H, van der Schaaf René J, Slagboom Ton, Vink Maarten A. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction. JACC Cardiovasc Interv. 2019;12:1691–9.CrossRef
11.
Zurück zum Zitat Elwany M, Palma GD, Cortese B. Treatment of coronary bifurcation lesions: current knowledge and future perspectives. Future Cardiol. 2018;14:165–79.CrossRef Elwany M, Palma GD, Cortese B. Treatment of coronary bifurcation lesions: current knowledge and future perspectives. Future Cardiol. 2018;14:165–79.CrossRef
12.
Zurück zum Zitat Leesar MA, Hakeem A, Azarnoush K, Thuesen L. Coronary bifurcation lesions: present status and future perspectives. Int J Cardiol. 2015;187:48–57.CrossRef Leesar MA, Hakeem A, Azarnoush K, Thuesen L. Coronary bifurcation lesions: present status and future perspectives. Int J Cardiol. 2015;187:48–57.CrossRef
13.
Zurück zum Zitat Perl L, Witberg G, Greenberg G, Vaknin-Assa H, Kornowski R, Assali A. Prognostic significance of the Medina classification in bifurcation lesion percutaneous coronary intervention with second-generation drug-eluting stents. Heart Vessels. 2020;35:331–9.CrossRef Perl L, Witberg G, Greenberg G, Vaknin-Assa H, Kornowski R, Assali A. Prognostic significance of the Medina classification in bifurcation lesion percutaneous coronary intervention with second-generation drug-eluting stents. Heart Vessels. 2020;35:331–9.CrossRef
14.
Zurück zum Zitat Collet C, Capodanno D, Onuma Y, et al. Left main coronary artery disease: pathophysiology, diagnosis, and treatment. Nat Rev Cardiol. 2018;15:321–31.CrossRef Collet C, Capodanno D, Onuma Y, et al. Left main coronary artery disease: pathophysiology, diagnosis, and treatment. Nat Rev Cardiol. 2018;15:321–31.CrossRef
15.
Zurück zum Zitat Asano T, Serruys PW, Collet C, et al. Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. Eur Heart J. 2018;39:3381–9.CrossRef Asano T, Serruys PW, Collet C, et al. Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. Eur Heart J. 2018;39:3381–9.CrossRef
16.
Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018)[J]. Circulation. 2018;138:e618–51.CrossRef Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018)[J]. Circulation. 2018;138:e618–51.CrossRef
17.
Zurück zum Zitat Suzuki N, Asano T, Nakazawa G, et al. Clinical expert consensus document on quantitative coronary angiography from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther. 2020;35:105–16.CrossRef Suzuki N, Asano T, Nakazawa G, et al. Clinical expert consensus document on quantitative coronary angiography from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther. 2020;35:105–16.CrossRef
18.
Zurück zum Zitat Zheng W, Li Y, Tian J, et al. Effects of ticagrelor versus clopidogrel in patients with coronary bifurcation lesions undergoing percutaneous coronary intervention. BioMed Res Int. 2019;2019:1–12. Zheng W, Li Y, Tian J, et al. Effects of ticagrelor versus clopidogrel in patients with coronary bifurcation lesions undergoing percutaneous coronary intervention. BioMed Res Int. 2019;2019:1–12.
19.
Zurück zum Zitat Zhang J, Ye F, Xu K, et al. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. Eur Heart J. 2020;41:2523–36.CrossRef Zhang J, Ye F, Xu K, et al. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. Eur Heart J. 2020;41:2523–36.CrossRef
20.
Zurück zum Zitat Naganuma T, Chieffo A, Meliga E, et al. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC Cardiovasc Interv. 2013;6:1242–9.CrossRef Naganuma T, Chieffo A, Meliga E, et al. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC Cardiovasc Interv. 2013;6:1242–9.CrossRef
21.
Zurück zum Zitat Ford TJ, McCartney P, Corcoran D, et al. Single- versus 2-stent strategies for coronary bifurcation lesions: a systematic review and meta-analysis of randomized trials with long-term follow-up. J Am Heart Assoc. 2018;7(11):e008730.CrossRef Ford TJ, McCartney P, Corcoran D, et al. Single- versus 2-stent strategies for coronary bifurcation lesions: a systematic review and meta-analysis of randomized trials with long-term follow-up. J Am Heart Assoc. 2018;7(11):e008730.CrossRef
22.
Zurück zum Zitat Chen S, Zhang J, Han Y, et al. Double kissing crush versus provisional stenting for left main distal bifurcation lesions: DKCRUSH-V randomized trial. J Am Coll Cardiol. 2017;70:2605–17.CrossRef Chen S, Zhang J, Han Y, et al. Double kissing crush versus provisional stenting for left main distal bifurcation lesions: DKCRUSH-V randomized trial. J Am Coll Cardiol. 2017;70:2605–17.CrossRef
23.
Zurück zum Zitat Burzotta F, Trani C, Todaro D, et al. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv. 2011;4:327–35.CrossRef Burzotta F, Trani C, Todaro D, et al. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv. 2011;4:327–35.CrossRef
24.
Zurück zum Zitat Chen S, Santoso T, Zhang J, et al. Clinical outcome of double kissing crush versus provisional stenting of coronary artery bifurcation lesions. Circ Cardiovasc Interv. 2017;10(2):e004497.CrossRef Chen S, Santoso T, Zhang J, et al. Clinical outcome of double kissing crush versus provisional stenting of coronary artery bifurcation lesions. Circ Cardiovasc Interv. 2017;10(2):e004497.CrossRef
25.
Zurück zum Zitat Tang Y, Qiao S, Su X, et al. Drug-coated balloon versus drug-eluting stent for small-vessel disease. JACC Cardiovasc Interv. 2018;11:2381–92.CrossRef Tang Y, Qiao S, Su X, et al. Drug-coated balloon versus drug-eluting stent for small-vessel disease. JACC Cardiovasc Interv. 2018;11:2381–92.CrossRef
26.
Zurück zum Zitat Lee W, Hsueh S, Chen C, et al. The comparison of clinical outcomes after drug-eluting balloon and drug-eluting stent use for left main bifurcation in-stent restenosis. Int Heart J. 2018;59:935–40.CrossRef Lee W, Hsueh S, Chen C, et al. The comparison of clinical outcomes after drug-eluting balloon and drug-eluting stent use for left main bifurcation in-stent restenosis. Int Heart J. 2018;59:935–40.CrossRef
27.
Zurück zum Zitat Harada Y, Colleran R, Pinieck S, et al. Angiographic and clinical outcomes of patients treated with drug-coated balloon angioplasty for in-stent restenosis after coronary bifurcation stenting with a two-stent technique. EuroIntervention. 2017;12:2132–9.CrossRef Harada Y, Colleran R, Pinieck S, et al. Angiographic and clinical outcomes of patients treated with drug-coated balloon angioplasty for in-stent restenosis after coronary bifurcation stenting with a two-stent technique. EuroIntervention. 2017;12:2132–9.CrossRef
28.
Zurück zum Zitat Berland J, Lefevre T, Brenot P, et al. DANUBIO-a new drug-eluting balloon for the treatment of side branches in bifurcation lesions: six-month angiographic follow-up results of the DEBSIDE trial. EuroIntervention. 2015;11:868–76.CrossRef Berland J, Lefevre T, Brenot P, et al. DANUBIO-a new drug-eluting balloon for the treatment of side branches in bifurcation lesions: six-month angiographic follow-up results of the DEBSIDE trial. EuroIntervention. 2015;11:868–76.CrossRef
29.
Zurück zum Zitat Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention. 2011;7 Suppl K:K61–5.CrossRef Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention. 2011;7 Suppl K:K61–5.CrossRef
30.
Zurück zum Zitat Belkacemi A, Agostoni P, Voskuil M, Stella P. Coronary bifurcation lesions treated with the drug-eluting balloon: a preliminary insight from the DEBIUT study. EuroIntervention. 2011;7 Suppl K:K66–9.CrossRef Belkacemi A, Agostoni P, Voskuil M, Stella P. Coronary bifurcation lesions treated with the drug-eluting balloon: a preliminary insight from the DEBIUT study. EuroIntervention. 2011;7 Suppl K:K66–9.CrossRef
31.
Zurück zum Zitat Lopez MJ, Nogales AJ, Doncel VL, et al. A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results. EuroIntervention. 2014;10:50–7.CrossRef Lopez MJ, Nogales AJ, Doncel VL, et al. A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABILON trial): 24-month clinical and angiographic results. EuroIntervention. 2014;10:50–7.CrossRef
32.
Zurück zum Zitat Goto K, Mintz GS, Litherland C, et al. Lumen measurements from quantitative coronary angiography and IVUS: A PROSPECT substudy. JACC Cardiovasc Imaging. 2016;9:1011–3.CrossRef Goto K, Mintz GS, Litherland C, et al. Lumen measurements from quantitative coronary angiography and IVUS: A PROSPECT substudy. JACC Cardiovasc Imaging. 2016;9:1011–3.CrossRef
33.
Zurück zum Zitat Lee J, Seo K, Yang H, et al. Comparison of three-dimensional quantitative coronary angiography and intravascular ultrasound for detecting functionally significant coronary lesions. Cardiovasc Diagn Ther. 2020;10:1256–63.CrossRef Lee J, Seo K, Yang H, et al. Comparison of three-dimensional quantitative coronary angiography and intravascular ultrasound for detecting functionally significant coronary lesions. Cardiovasc Diagn Ther. 2020;10:1256–63.CrossRef
34.
Zurück zum Zitat Tomaniak M, Masdjedi K, Zandvoort LJ, et al. Correlation between 3D-QCA based FFR and quantitative lumen assessment by IVUS for left main coronary artery stenoses. Catheter Cardiovasc Interv. 2021;97:E495–501.CrossRef Tomaniak M, Masdjedi K, Zandvoort LJ, et al. Correlation between 3D-QCA based FFR and quantitative lumen assessment by IVUS for left main coronary artery stenoses. Catheter Cardiovasc Interv. 2021;97:E495–501.CrossRef
35.
Zurück zum Zitat Vergallo R, Porto I, De Maria GL, et al. Dual quantitative coronary angiography accurately quantifies intracoronary thrombotic burden in patients with acute coronary syndrome: comparison with optical coherence tomography imaging. Int J Cardiol. 2019;292:25–31.CrossRef Vergallo R, Porto I, De Maria GL, et al. Dual quantitative coronary angiography accurately quantifies intracoronary thrombotic burden in patients with acute coronary syndrome: comparison with optical coherence tomography imaging. Int J Cardiol. 2019;292:25–31.CrossRef
36.
Zurück zum Zitat Gil RJ, Bil J, Legutko J, et al. Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up. Int J Cardiovasc Imaging. 2018;34:353–65.CrossRef Gil RJ, Bil J, Legutko J, et al. Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up. Int J Cardiovasc Imaging. 2018;34:353–65.CrossRef
37.
Zurück zum Zitat Rittger H, Waliszewski M, Brachmann J, et al. Long-term outcomes after treatment with a paclitaxel-coated balloon versus balloon angioplasty: insights from the PEPCAD-DES study (treatment of drug-eluting stent [DES] in-stent restenosis with SeQuent Please paclitaxel-coated percutaneous transluminal coronary angioplasty [PTCA] Catheter). JACC Cardiovasc Interv. 2015;8:1695–700.CrossRef Rittger H, Waliszewski M, Brachmann J, et al. Long-term outcomes after treatment with a paclitaxel-coated balloon versus balloon angioplasty: insights from the PEPCAD-DES study (treatment of drug-eluting stent [DES] in-stent restenosis with SeQuent Please paclitaxel-coated percutaneous transluminal coronary angioplasty [PTCA] Catheter). JACC Cardiovasc Interv. 2015;8:1695–700.CrossRef
38.
Zurück zum Zitat Candy N, Ng E, Velu R. Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty. J Vasc Surg. 2017;65:558–70.CrossRef Candy N, Ng E, Velu R. Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty. J Vasc Surg. 2017;65:558–70.CrossRef
Metadaten
Titel
Effect of Paclitaxel-Coated Balloon Angioplasty on Side Branch Lesion and Cardiovascular Outcomes in Patients with De Novo True Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
verfasst von
Youmei Li
Qi Mao
Huanyun Liu
Denglu Zhou
Jianhua Zhao
Publikationsdatum
09.07.2021
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 5/2022
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07225-8

Weitere Artikel der Ausgabe 5/2022

Cardiovascular Drugs and Therapy 5/2022 Zur Ausgabe

So beeinflussen Herzinfarkte auf lange Sicht die Sterblichkeit

20.06.2024 ST-Hebungsinfarkt Nachrichten

Wie hoch ist bei Patienten, die nach einem ST-Hebungs-Myokardinfarkt die initiale Hochrisikophase überleben, auf lange Sicht das Sterberisiko? Eine Studie aus Dänemark liefert dazu nun aufschlussreiche Daten.

Protonenpumpenhemmer stoppt Arrhythmie

20.06.2024 Protonenpumpenhemmstoffe Nachrichten

Wenn Nervenfasern aus dem Magen und dem Herzen im Gehirn dicht beieinander liegen, kann auch mal etwas schiefgehen: So lässt sich erklären, weshalb Schmerzen durch einen Magentumor bei einem Mann eine ventrikuläre Extrasystolie auslösen – und PPI diese beenden.

Ob Apixaban nützt oder schadet, entscheidet der CHA2DS2-VASc-Score

20.06.2024 Therapie des Vorhofflimmerns Nachrichten

Patienten mit subklinischem Vorhofflimmern tragen ein erhöhtes Risiko für Schlaganfälle. Da stellt sich die Frage nach einer medikamentösen Antikoagulation. Offenbar hängt es aber vom CHA2DS2-VASc-Score ab, ob die Gabe von Apixaban von Vorteil ist.

Wie SGLT2-Hemmer es schaffen, die Mortalität zu reduzieren

20.06.2024 Kardiologische Therapie Nachrichten

SGLT2-Hemmer verhindern keine Herzinfarkte oder Schlaganfälle. Aber sie reduzieren die kardiovaskuläre Mortalität bei einem breiten Spektrum von Patienten. Wie sie das schaffen, verdeutlicht eine Metaanalyse von Daten aus elf randomisierten Studien.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.